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Acute extremity ischemia and reperfusion (I/R)
initiates a complex inflammatory cascade that can
result in injury to both the ischemic extremity (local
injury) and tissues outside the ischemic field (distant
injury). Multiple studies1-3 have reported that the
proinflammatory cytokine tumor necrosis factor a
(TNF- a ) causes pulmonary injury after hindlimb
I/R in a rat model. However, the role of TNF-a in
generating or extending the muscle injury in the
affected extremity is less clear. Seekamp et al2 report-
ed that TNF-a blockade reduced the muscle vascu-
lar injury in a rat hindlimb I/R model. In contrast,
Sternbergh et al4 found that pretreatment with anti-
TNF-a antibody did not attenuate the skeletal mus-
cle injury nor the vascular permeability after I/R in
an isolated rat hindlimb model. Furthermore, Ascer
et al5 reported that TNF was not detectable in the
venous effluent during reperfusion in a canine gra-
cilis muscle preparation after 6 hours of ischemia.
This study tested the hypothesis that TNF is respon-
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Purpose: Tumor necrosis factor a (TNF-a ) has been shown to play a role in pulmonary
injury after lower-extremity ischemia/reperfusion (I/R). However, its role in direct
skeletal muscle injury is poorly understood. The hypothesis that endogenous TNF pro-
duction contributes to skeletal muscle injury after hindlimb I/R in rats was tested.
Methods: Juvenile male Sprague-Dawley rats underwent 4 hours of bilateral hindlimb
ischemia and 4 hours of reperfusion (IR) or sham operation (SHAM). A subset was
treated with a soluble TNF receptor I construct (STNFRI, 10 mg/kg) 1 hour before
ischemia (PRE) or at reperfusion (POST). Direct skeletal muscle injury (SMII) and
muscle endothelial capillary permeability (MPI) were quantified by means of Tc99
pyrophosphate and I125 albumin uptake. Pulmonary neutrophil infiltration and hepato-
cellular injury were assessed by means of myeloperoxidase content (MPO) and aspartate
aminotransferase (AST) concentrations, respectively. Serum TNF bioactivity was mea-
sured with the WEHI bioassay.
Results: Hindlimb I/R (IR vs SHAM) resulted in a significant (P < .05) increase in the
SMII (0.52 ± 0.06 vs 0.07 ± 0.01) and MPI (0.35 ± .04 vs 0.06 ± 0.01). Pretreatment
with STNFRI (PRE vs IR) significantly ameliorated both SMII (0.30 ± 0.05 vs 0.52 ±
0.06) and MPI (0.23 ± 0.02 vs 0.35 ± 0.04), whereas treatment at reperfusion (POST
vs IR) had no effect. Hindlimb I/R (IR vs SHAM) resulted in both significant pul-
monary neutrophil infiltration (MPO 16.4 ± 1.06 U/g vs 11.3 ± 1.4 U/g) and hepa-
tocellular injury (AST 286 ± 45 U/mL vs 108 ± 30 U/mL), but neither was inhibited
by pretreatment with STNFRI before ischemia. Detectable levels of TNF were measured
during ischemia in a significantly higher percentage of the IR group compared with
SHAM (9 of 12 vs 3 of 12), and the maximal TNF values were also significantly greater
(51.1 ± 12.6 pg/mL vs 5.5 ± 2.9 pg/mL). No TNF was detected in any treatment group
during reperfusion nor after administration of the STNFRI.
Conclusion: Acute hindlimb IR initiates a systemic TNF response during the ischemic
period that is partly responsible for the associated skeletal muscle injury. (J Vasc Surg
1999;29:370-6.)
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sible for the direct skeletal muscle injury in a rat
hindlimb I/R model.
METHODS
Experimental design. In the initial series of
experiments, animals were randomly assigned to
bilateral hindlimb I/R (IR), bilateral hindlimb I/R
with soluble TNF receptor I construct (STNFRI)
given before ischemia (PRE), or sham operation
(SHAM). Serum samples were collected during both
ischemia and reperfusion for TNF assay and during
reperfusion only for aspartate aminotransferase con-
centrations. The animals were killed after 4 hours of
reperfusion, and the lungs were harvested for quan-
tification of neutrophil infiltration, and the hindlimb
skeletal muscle was harvested for measurement of
the vascular permeability and cellular injury. In the
second, similar series of experiments, the significance
of the TNF detected during ischemia was examined.
Animals were randomly assigned to bilateral
hindlimb I/R, STNFRI given before reperfusion
(POST), or sham operation. Serum samples were
collected during ischemia and reperfusion for TNF
assay, and skeletal muscle was harvested after 4 hours
of reperfusion for measurement of vascular perme-
ability and cellular injury.
Animal model.6 Juvenile male Sprague-Dawley
rats (200 to 250 g) were anesthetized with 40
mg/kg pentobarbital intraperitoneally (Nembutal,
Abbott Laboratories, North Chicago, Ill). A
catheter was placed into the atrialcaval junction
through the right external jugular vein and infused
with physiologic saline solution at 1 mL/h.
Complete bilateral hindlimb ischemia was produced
by means of tourniquet occlusion of the upper
thighs, and the cessation of arterial flow was con-
firmed by means of the absence of an audible con-
tinuous wave Doppler signal in the superficial
Fig 1. Skeletal muscle injury index (SMII) as measured by
means of the uptake of Tc99 pyrophosphate in the soleus
muscle. Animals were subjected to bilateral hindlimb
ischemia (IR), bilateral hindlimb ischemia and pretreat-
ment with STNFRI (PRE), bilateral hindlimb ischemia
and STNFRI treatment at time of reperfusion (POST), or
sham operation (SHAM). The values were compared with
one-way analysis of variance, and the significant differ-
ences were identified with either the Student-Newman-
Keuls or Dunn test. A P value less than .05 was accepted
as significant and is marked with an *.
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Fig 2. Skeletal muscle capillary membrane permeability
index (MPI), as measured by means of the uptake of I125
albumin in the soleus muscle. Animals were subjected to
bilateral hindlimb ischemia (IR), bilateral hindlimb
ischemia and pretreatment with STNFRI (PRE), bilateral
hindlimb ischemia and STNFRI treatment at time of
reperfusion (POST), or sham operation (SHAM). The val-
ues were compared with one-way analysis of variance, and
the significant differences were identified with either the
Student-Newman-Keuls or Dunn test. A P value less than
.05 was accepted as significant and is marked with an *.
B
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femoral artery. After 4 hours of ischemia, the tourni-
quets were released and the extremities reperfused.
Reperfusion was confirmed by means of the restora-
tion of the superficial femoral artery Doppler signal.
Sham controls were treated similarly; however, the
tourniquets were not applied to the thighs. Blood
samples (0.5 mL) were withdrawn from the catheter
at specific times during both the ischemia and reper-
fusion periods and at comparable points in the sham
controls. The blood samples were centrifuged to
remove the cellular components, and the serum was
stored at –70°C. The blood volume sampled was
replaced with three times the volume of physiologic
saline solution. The animals were killed with lethal
injection (25 mg of pentobarbital intravenously) at
various times.
Soluble tumor necrosis factor receptor I con-
struct. The STNFRI (Amgen, Bolder, Colo) binds
both TNF-a and TNF-b with high affinity and inhibits
both in vitro and in vivo TNF activity.7 The STNFRI
is composed of the extracellular domain of two human
TNF p55 receptors covalently bound to 20 kd poly-
ethylene glycol. The dosage (10 mg/kg) selected was
twice that previously demonstrated to protect the
baboons (Papio) species from lethal Escherichia coli
sepsis.8 The STNFRI was given intravenously 1 hour
before ischemia in the PRE group and immediately
before reperfusion in the POST group.
Assessment of vascular permeability and
skeletal muscle cellular injury. Skeletal muscle cap-
illary endothelial cell injury was quantified by means
of uptake of I125-labeled albumin.2,4 Skeletal muscle
cellular injury was quantified by means of uptake of
Tc99-labeled pyrophosphate.4,9 0.4 m Ci of I125-
labeled bovine serum albumin and 0.5 MCi of Tc99-
labeled pyrophosphate were given intravenously just
before reperfusion and at comparable times for the
sham controls. At the time of killing, the femoral
artery of one leg was cannulated with a 27-gauge
catheter and flushed with 60 mL of physiologic
saline solution. After flushing, the soleus muscle was
harvested, washed with physiologic saline solution,
weighed, and the muscle I125 and Tc99 uptake was
determined by means of gamma counting. Similarly,
0.5 mL of blood was withdrawn from the inferior
vena cava at the time of killing; it was weighed, and
the I125 and Tc99 counts were determined. Mean
endothelial permeability index (MPI) and skeletal
muscle injury index (SMII) were then calculated:
MPI = (I125 muscle/muscle weight [g])/(I125
blood/blood weight [g])
SMII = (Tc99 muscle/muscle weight [g])/(Tc99
blood/blood weight [g]).
Assessment of pulmonary neutrophil infiltra-
tion. Pulmonary neutrophil infiltration was quanti-
fied by means of myeloperoxidase (MPO) levels.6-10
Fig 4. Hepatocellular injury, as measured by means of
serum aspartate aminotransferase (AST) concentrations
versus time. A time of –4 represents AST concentrations at
baseline (insertion of atrialcaval catheter) before the onset
of ischemia. A time of 0 represents the onset of reperfu-
sion. Animals were subjected to bilateral hindlimb
ischemia (IR), bilateral hindlimb ischemia and pretreat-
ment with STNFRI (PRE), or sham operation (SHAM).
The values were compared with one-way analysis of vari-
ance, and the significant differences were identified with
the Student-Newman-Keuls test. A P value less than .05
was accepted as significant. A significant difference
between the IR and SHAM group is marked with an *,
whereas a significant difference between the PRE and
SHAM groups is marked with a #.
Fig 3. Pulmonary neutrophil sequestration, as measured
by means of lung myeloperoxidase content (MPO).
Animals were subjected to bilateral hindlimb ischemia
(IR), bilateral hindlimb ischemia and pretreatment with
STNFRI (PRE), or sham operation (SHAM). The values
were compared with one-way analysis of variance, and the
significant differences were identified with a Student-
Newman-Keuls test. A P value less than .05 was accepted
as significant and is marked with an *.
Laboratory Animal Resources, Commission on Life
Sciences, National Research Council: National
Academy Press, 1996.)
RESULTS
Skeletal muscle injury. Lower-extremity I/R
resulted in a significant skeletal muscle cellular injury
(SMII). The SMII in the soleus muscle of the IR
group was significantly greater than the SHAM con-
trols in both the initial (Fig 1A: 0.52 ± 0.06 vs 0.07
± 0.01) and subsequent (Fig 1B: 0.55 ± 0.09 vs 0.08
± 0.01) series of experiments. Treatment with the
STNFRI before ischemia (Fig 1A) resulted in a sig-
nificant reduction (42%) in the SMII (PRE, 0.30 ±
0.05). However, the STNFRI was not entirely pro-
tective against the I/R-induced skeletal muscle
injury, because the SMII in the PRE animals was still
significantly greater than that of the SHAM con-
trols. In contrast, treatment with the STNFRI just
before reperfusion (Fig 1B) resulted in no protec-
tion from the I/R-induced muscle injury, because
the SMII in the POST group (0.74 ± 0.07) was not
significantly different from that of the IR group.
Skeletal muscle capillary membrane perme-
ability. Lower-extremity I/R resulted in a signifi-
cant increase in the skeletal muscle capillary
endothelial permeability index (MPI). The MPI in
the soleus muscle of the IR group was significantly
greater than that of the SHAM controls in both the
initial (Fig 2A, 0.35 ± 0.04 vs 0.06 ± 0.01) and sub-
sequent (Fig 2B, 0.46 ± 0.07 vs 0.06 ± 0.01) series
of experiments. Again, treatment with the STNFRI
before ischemia (Fig 2A) resulted in a significant
decrease (29%) in the MPI (PRE, 0.23 ± 0.02), but
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Lung tissues were harvested at the time of killing,
immediately washed with physiologic saline solu-
tion, and flash frozen in liquid nitrogen. The frozen
tissues were then stored at –70°C. Thawed lung
samples were weighed, homogenized in 0.01 M
KH2PO4 at a ratio of 1 to 15 weight for volume, and
the resultant pellets were resuspended in cetyl-
trimethylammonium bromide buffer at a ratio of 1
to 5 weight for volume. This solution was incubated
at 60°C for 2 hours and sonicated for 1 minute. The
MPO concentration of the supernatant was mea-
sured by the H202-dependent oxidation of 3,3¢ ,5,5¢ -
tetramethylbenzidine. Absorbance was determined
at 650 nm and compared with a linear standard
curve (sensitivity to 0.0625 units).
Assessment of liver injury. Hepatocellular
injury was quantified by means of serum aspartate
aminotransferase (AST) concentrations with a com-
mercially available kit (Sigma Chemical, St. Louis,
Mo). The measurement of AST with this system is
based on the generation of chromogenic phenylhy-
drazines. The serum samples and the standard con-
centrations were diluted 1 to 2, and absorbance was
determined at 505 nm.
Serum tumor necrosis factor measurement.
Circulating bioactive TNF was measured with the
TNF sensitive WEHI murine fibrosarcoma cell
line.11 The cells were cultured on 96 well plates and
exposed, in the presence of 1 m g/mL actinomycin
D, to either serum samples diluted 1 to 5 with cul-
ture medium or standard concentrations of human
TNF-a . Cellular viability was determined by means
of the uptake of MTT (3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide) and quanti-
fied by means of the absorbance at 570 nm.
Recombinant human TNF-a was used as a standard,
and the sensitivity of the assay was 5 pg/mL.
Statistical method. Data are presented as mean
± one standard error of the mean (SEM). The SMII,
MPI, MPO, and AST values were compared by
means of a one-way analysis of variance, and the sig-
nificant differences were identified by means of either
the Student-Newman-Keuls or Dunn test. The fre-
quency of detecting TNF in the plasma was com-
pared by means of the Fisher exact test; the mean
concentrations of TNF were compared by means of
the two-way analysis of variance; and the maximal
TNF levels were compared by means of the rank sum
test. A P value less than .05 was considered signifi-
cant. The study was approved by the Institution
Animal Care and Use Committee at the University 
of Florida and complied with the Guide for the 
Care and Use of Laboratory Animals (Institute of
Fig 5. The maximal tumor necrosis factor (TNF) levels
during the ischemic period for the treatment groups.
Animals were subjected to bilateral hindlimb ischemia
(IR) or sham operation (SHAM). The values were com-
pared with a rank sum test. A P value less than .05 was
accepted as significant and is marked with an *.
the STNFRI was not completely protective, because
the MPI in the PRE group was still significantly
greater than that of the SHAM controls. Further-
more, treatment with the STNFRI at reperfusion
(Fig 2B) resulted in no protection from I/R-
induced muscle capillary endothelial injury, because
the MPI in the POST group (0.59 ± 0.03) was not
significantly different from that of IR group.
Lung myeloperoxidase. Lower-extremity I/R
resulted in significant pulmonary neutrophil seques-
tration (Fig 3). The MPO levels in the IR group
were 16.4 ± 1.06 U/g, vs 11.3 ± 1.4 U/g in the
SHAM controls. However, the STNFRI did not
protect against the lower extremity I/R-induced
lung injury, because there was no significant differ-
ence between the values in the IR and PRE groups
(PRE, 16.8 ± 1.6 U/g).
Hepatocellular injury. Lower-extremity I/R
also resulted in a significant hepatocellular injury
(Fig 4). The serum AST levels in the IR group were
significantly greater than those in the SHAM con-
trols, beginning 2 hours after reperfusion. Again,
the STNFRI did not protect against lower-extremi-
ty I/R-induced hepatic injury, because there was no
difference between the serum AST concentrations in
the IR and the PRE groups at any time.
Serum tumor necrosis factor. Detectable levels
of TNF (more than 5 pg/mL) were measured in the
serum of 75% (9 of 12) of the IR group, but only
25% (3 of 12) of the SHAM controls, during the
ischemic period (P = .02). The time course of the
mean TNF response during ischemia was significant-
ly different in the IR group when compared with
SHAM controls by two-way analysis of variance, but
there were no significant differences in the mean val-
ues between the two groups for any specific time.
Additionally, the maximal TNF levels were sig-
nificantly greater in the IR group (51.1 ± 12.6
pg/mL vs 5.5 ± 2.9 pg/mL) during the ischemic
period (Fig 5). In contrast, no TNF was detected at
any time (0.5 hour, 1 hour, 1.5 hours, 2 hours) in
either the IR or SHAM groups during reperfusion,
and no TNF was detectable in the serum during
either ischemia (PRE) or reperfusion (PRE and
POST) in the subset of animals given the STNFRI.
DISCUSSION
This study demonstrates that hindlimb I/R causes
injury to both the ischemic skeletal muscle and to
tissues outside the ischemic field. Furthermore, TNF
was partly responsible for the skeletal muscle injury,
but did not appear to contribute to either the pul-
monary neutrophil infiltration or hepatic injury.
Surprisingly, the TNF was released during the
ischemic period, rather than after reperfusion, and
TNF blockade was effective in reducing the skeletal
muscle injury only when given before the ischemic
period.
The results support the hypothesis that the local
skeletal muscle injury after I/R is mediated in part
by TNF. These findings corroborate those of
Seekamp et al,2 who reported that abrogating TNF-
a activity with a soluble TNF receptor construct and
an anti-TNF-a antibody decreased muscle capillary
permeability after muscle I/R. However, the present
study is the first, in our knowledge, to demonstrate
that blocking TNF activity limits skeletal muscle cel-
lular injury after lower-extremity I/R. The current
findings are also consistent with 2 earlier reports
from our laboratory. Engles et al6 reported that a
matrix metalloprotease inhibitor that blocks TACE
(TNF converting enzyme activity) and prevents the
release of membrane-bound TNF- a reduced the
skeletal muscle injury after hindlimb I/R in rats.
Furthermore, Engles et al6 reported that the anti-
inflammatory cytokine IL-10 inhibited skeletal mus-
cle injury I/R in a similar rat model. Admittedly, the
latter evidence is indirect because IL-10 is pluripo-
tent and has been shown to downregulate the proin-
flammatory cytokines TNF, IL-1, and IL-8,13-15 as
well as adhesion molecule expression.16,17 Our
results contradict those of Sternbergh et al,4 who
were unable to demonstrate a reduction in skeletal
muscle injury after pretreatment with an anti-TNF-
a antibody in an ex vivo isolated hindlimb model.
They detected TNF in the extremity effluent imme-
diately on reperfusion, but did not detect any effect
of TNF blockade on either capillary membrane per-
meability or skeletal muscle uptake of Tc99
pyrophosphate. The inconsistencies between our
findings and those of Sternbergh et al4 may be
caused by the short duration of ischemia (2 hours)
and reperfusion (1 hour) in their study and the ex
vivo preparation. Additional serum elements, such as
complement (which were not present in their ex vivo
model), may be necessary for TNF to exert its effects
after I/R.18,19
The finding that TNF did not contribute to the
pulmonary neutrophil infiltration or hepatic injury
after hindlimb I/R was surprising. Both Seekamp et
al2 and Welbourn et al1 reported that TNF blockade
inhibited pulmonary capillary leak and neutrophil
infiltration after hindlimb I/R in rats. Similarly,
Tassiopoulos et al3 reported that the histologic pul-
monary injury after lower torso I/R in rats was par-
tially reversed with TNF blockade. The discrepancies
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between the findings in our study and the findings
of others may be caused by a variety of factors,
including differences in experimental design, dura-
tion of ischemia, extent of ischemic field, rat strain,
and/or differences in the specificity of the TNF
blocking agent. Furthermore, it should be noted
that the lung MPO assay that was used as a marker
of neutrophil infiltration in our study does not nec-
essarily equate with lung injury, although neu-
trophils are postulated to be the primary mediator of
the distant organ injury after I/R.20 This limitation
is emphasized by the report of Engles et al6 in which
exogenous IL-10 led to a significant decrease in pul-
monary capillary injury after hindlimb I/R in rats,
despite a significant increase in pulmonary neu-
trophil infiltration (MPO).
The observation that TNF was released during
the ischemic period, but not after reperfusion, was
counterintuitive. We had hypothesized that reperfu-
sion of the ischemic hindlimb would result in the
release of a variety of proinflammatory mediators,
including TNF. Indeed, Seekamp et al2 reported
that the plasma levels of TNF-a were undetectable
after 4 hours of ischemia, but increased after reper-
fusion, with peak levels detected after 60 minutes. In
addition, Welbourn et al1 reported that there was a
measurable increase in serum TNF in four of six rats
after hindlimb I/R, although the values did not
achieve significance; samples from the ischemic peri-
od were not assayed for TNF. However, our findings
are consistent with those of Tassiopoulos et al,3 who
reported a significant increase in serum TNF-a lev-
els during ischemia in a rat lower-torso I/R model.
The TNF- a levels in their study peaked after 60
minutes of ischemia and returned to baseline by the
onset of the reperfusion period. Similarly, Barry et
al21 reported that infrarenal aortic crossclamp appli-
cation during aneurysm repair in humans resulted in
a significant increase in plasma TNF during the peri-
od of lower-torso ischemia and that TNF levels dur-
ing reperfusion were not different from the baseline
values. The significance of the TNF released during
the ischemic period was confirmed with our experi-
ments, in which the STNFRI was administered
before ischemia and just before reperfusion. The
STNFRI decreased I/R-induced skeletal muscle
injury when given before the ischemic period, but
failed to provide any protection from the skeletal
muscle injury when given just before reperfusion.
This observation is in direct contradiction with the
reports of Seekamp et al2 and Welbourn et al,1 in
which the TNF blockade administered before reper-
fusion conferred protection against both the pul-
monary (Seekamp and Welborn) and skeletal muscle
injury (Seekamp).
The role of TNF as a mediator of the skeletal
muscle injury was established primarily by means of
TNF inhibition with the STNFRI. This product and
other similar inhibitors have proven very helpful in
defining the mechanisms responsible for the inflam-
matory response. However, there is a degree of
uncertainty associated with their specificity, because
it is conceivable that they may bind to other media-
tors in addition to TNF. Indeed, antibodies to
ICAM-I, the cellular adhesion molecule, have been
shown to confer protection against I/R injury inde-
pendent of their antibody-blocking function.22
Future studies with animals genetically deficient for
a specific inflammatory mediator may definitively
resolve these types of issues.23
The observations that the TNF did not con-
tribute to the distant organ injury and that STNFRI
was not beneficial when administered at the time of
reperfusion were both negative observations. It is
possible that the experimental design and sample size
were inadequate to detect a subtle injury or benefit.
The clinical use of specific anti-TNF agents remains
unclear in light of the observation that the TNF
response was initiated during the ischemic period.
Patients with acute visceral, lower-extremity, or
myocardial ischemia usually do not seek medical
attention until after they have symptoms from the
end-organ ischemia. Our data suggest that the
inflammatory responses that lead to the sequelae of
I/R injury may already be initiated by this point and,
therefore, may be less amenable to therapy. Thus,
anti-TNF therapies may be most useful in the setting
of a controlled I/R injury, such as elective lower-
extremity revascularization or aortic aneurysm repair.
In conclusion, acute hindlimb IR initiates a sys-
temic TNF response during the ischemic period that
is partly responsible for the resulting skeletal muscle
injury.
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